Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 4/20 | 0.63 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076566 | 0.82 | SLC6A4 (0.54) | PYCR1SLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL24365508 | 0.81 | TAAR1 (0.56) | PYCR1CCR5SLC6A4ALDH1A1KDM4E | |
| SCHEMBL16553471 | 0.79 | PYCR1 (0.61) | PYCR1SLC6A4SLC6A2SLC6A3KDM4E | |
| SCHEMBL11452260 | 0.78 | PYCR1 (0.51) | PYCR1CCR5SLC6A4ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8648703 | 0.78 | PYCR1 (0.59) | PYCR1SLC6A4SLC6A2SLC6A3KDM4E | |
| SCHEMBL27471130 | 0.77 | PYCR1 (0.51) | PYCR1CCR5SLC6A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL257075 | 0.77 | PYCR1 (0.50) | PYCR1SLC6A4ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3197622 | 0.76 | SLC6A4 (0.54) | PYCR1SLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL21419342 | 0.76 | PYCR1 (0.63) | PYCR1CCR5SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL16621211 | 0.76 | SLC6A4 (0.50) | PYCR1CCR5SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519267-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2025-03-12 | — | — | EP | disclosed |
| US-20250066372-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-02-27 | — | — | US | disclosed |
| CN-119156389-A | Heterocyclic compounds, compositions thereof and methods of treatment thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2023213271-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066372-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CDK1, CDK2, CDK4 | PYCR1 2773/4885CCR5 4519/4885SLC6A4 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.